Clinical Trial Search

Primary: To Evaluate the Safety and Tolerability of Escalating Doses of the MM-121 Anticancer Therapies — 3; 8; 5; 3 participants reporting adverse events

Primary: Adverse Events — 3; 6 participants

Primary: Mean Change in Hemoglobin Concentration (g/dL) From Baseline to Evaluation Period — 0.05; -0.10 gram per deciliter (g/dL) — p=< 0.0001

Primary: Number of Participants Who Experienced Dose-limiting Toxicities (DLTs) — 0; 2 participants

Primary: The Percentage of Patients Who Had a Curative (R0) Liver Metastasectomy Following Protocol Treatment, i.e., Metastatic Disease That Can be Completely Resected and/or…

Primary: Patients With Low-density Lipoprotein (LDL) Cholesterol Reduction — 90.9 percentage of participants

Primary: Percentage of Subjects With First Reoperation Following Use of a BIOCELL™ Textured 410 Implant — 28 Percentage of Subjects

Primary: Functional Assessment of Cancer Therapy-Fatigue Subscale (FACIT-F) at Day 29 (+/- 3 Days) — 12; 13; 12; 14 units on a scale

Primary: Pain Intensity Difference (PID) From Pre-dose Baseline to 8h After the First Trial Medication Application (PID8h) — -0.98; -2.82 points on a scale — p=<0.0001

Primary: Change of Forced Expiratory Volume in 1 Second (FEV1) From Pre-bronchodilator at Baseline to Post-nebulization One Day Before the Surgery — 169.9; 15.0 ml — p=<0.0001

Primary: Hemostasis at the Target Bleeding Site (TBS) at 10 Minutes Following the Completion of Treatment Application. — 96; 88.2 percentage of patients

Primary: Area Under the Plasma Effect-time Curve Over 96 Hours (AUEC[0-96 h]) for International Normalized Ratio (INR) — -2.16; -9.06 hours*ratio

Primary: Number of Participants With Successful Intubations on First Attempt; Grade(s) Were Not Measured. — 29; 36 participants

Primary: Change in Flow-mediated Dilation (FMD) — 1.1; -0.9 change in percent flow-mediated dilation

Primary: Incidence of Vincristine-induced Peripheral Neuropathy — 24; 25 participants